- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ERASCA Aktie jetzt für 0€ handeln | |||||
| 12.05. | Mizuho cuts Erasca stock price target on acquisition payment | 7 | Investing.com | ||
| 11.05. | Erasca GAAP EPS of -$0.60 | 2 | Seeking Alpha | ||
| 11.05. | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | 160 | GlobeNewswire (Europe) | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| 11.05. | Erasca, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Erasca, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.05. | Kooperation mit Merck bei Krebsmedikament treibt Erasca-Aktie an | 11 | Investing.com Deutsch | ||
| 11.05. | Erasca teams up with Merck to test ERAS-0015 with Keytruda, shares jump | 3 | Seeking Alpha | ||
| 11.05. | Erasca, Inc.: Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA (Pembrolizumab) | 326 | GlobeNewswire (Europe) | SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| 11.05. | JPMorgan Recommends Buying Erasca (ERAS) Stock at Current Levels | 6 | Insider Monkey | ||
| 29.04. | Patient Death Drags Erasca (ERAS) Shares by 48% | 24 | Insider Monkey | ||
| 28.04. | TD Cowen bekräftigt Kaufempfehlung für Revolution Medicines nach Daten von Konkurrent Erasca | 44 | Investing.com Deutsch | ||
| 28.04. | FDA claims Amgen drug data were 'manipulated'; Erasca slides despite 'home run' results | 15 | BioPharma Dive | ||
| 28.04. | Erasca hits 'home run' with cancer data as analyst suggests stock drop prompted by patient death | 4 | FierceBiotech | ||
| 28.04. | H.C. Wainwright reiterates Erasca stock rating on phase 1 data | 3 | Investing.com | ||
| 28.04. | Revolution Medicines rival Erasca falls after early-stage trial data for cancer therapy | 18 | Seeking Alpha | ||
| 28.04. | BofA raises Erasca stock price target to $9 on trial data | 6 | Investing.com | ||
| 27.04. | Erasca meldet positive frühe Studiendaten für Pan-RAS-Medikament | 3 | Investing.com Deutsch | ||
| 27.04. | Erasca reports positive early trial data for pan-RAS drug | 13 | Investing.com | ||
| 27.04. | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | 296 | GlobeNewswire (Europe) | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| 27.04. | Stifel raises Erasca stock price target to $30 on RAS program | 16 | Investing.com |
1 2 3 4 Weiter >>
72 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 76,50 | +1,06 % | Tagesvorschau 15. Mai: Biontech-HV, BVB-Quartal, US-Industriedaten - das bringt der Freitag | Die turbulente Bilanzwoche klingt aus - doch der Freitag hält für Anleger noch einige spannende Termine bereit.Zum Wochenausklang dünnt der Terminkalender zwar aus, gewinnt aber spürbar an Schärfe.... ► Artikel lesen | |
| MODERNA | 39,400 | +0,03 % | Hedge Fund and Insider Trading News: Bill Ackman, Ray Dalio, Warren Buffett, Viking Global, Darsana Capital Partners, Caxton Associates, Balyasny Asset Management, D1 Capital Partners, Republic Services Inc (RSG), Moderna Inc (MRNA), and More | ||
| PAION | 0,072 | -25,52 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| NOVAVAX | 7,670 | -0,13 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| ILLUMINA | 121,30 | -0,61 % | RBC Capital assumes Illumina stock coverage with outperform rating | ||
| NANOREPRO | 1,570 | 0,00 % | NanoRepro: Mit Elan gestartet | "Wir sind auf einem guten Weg", sagt Lisa Jüngst, CEO von NanoRepro, am Ende ihrer Präsentation auf der Frühjahrskonferenz in Frankfurt. Die Aufgabenstellung könnte dabei ambitionierter kaum sein. Immerhin... ► Artikel lesen | |
| 4SC | 0,100 | -23,37 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.12.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 16.12.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.12.2025ISIN NameDE000A3E5C40 4SC... ► Artikel lesen | |
| VIVOSIM LABS | 1,320 | +3,94 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,130 | +7,01 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 actively being reviewed under the accelerated approval program by the U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| INFLARX | 2,050 | -0,68 % | SCHOCKMELDUNG bei InflaRx NV: Warum Sie jetzt genau hinschauen sollten - Handeln Sie, bevor es zu spät ist! | ||
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| DEFENCE THERAPEUTICS | 0,299 | +2,05 % | Defence Therapeutics Inc.: Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities | Montreal, Quebec--(Newsfile Corp. - May 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| EDITAS MEDICINE | 2,100 | -1,41 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,562 | +0,03 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| IBIO | 1,263 | -3,29 % | iBio, Inc.: iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors | SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases announced today the appointment... ► Artikel lesen |
Das Unternehmen ERASCA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 10,320 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ERASCA INC finden Sie auf Wallstreet Online.